BMS 986171
Alternative Names: BMS986171Latest Information Update: 29 Feb 2020
At a glance
- Originator Bristol-Myers Squibb
- Class Antifibrotics; Fibroblast growth factors; Hepatoprotectants
- Mechanism of Action Fibroblast growth factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 08 Nov 2019 Pharmacodynamics data from a preclinical trial in Non-alcoholic fatty liver) presented at the 70th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2019)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Hepatic-fibrosis(In volunteers) in USA (SC, Injection)
- 28 Nov 2018 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in USA (SC, Injection)